nx-019

NX-019 is an orally bioavailable, central nervous system (CNS)-penetrant, mutant-selective epidermal growth factor receptor (EGFR) inhibitor. It is designed to target a broad spectrum of EGFR mutations—including common mutations such as exon 19 deletions and exon 21 L858R, as well as rare mutations like T790M, exon 20 insertions (ex20ins), G719S, and L861Q. NX-019 exhibits high selectivity for mutant EGFR over wild-type EGFR in preclinical studies and demonstrates substantial CNS exposure with potent anti-tumor activity in intracranial xenograft models. The drug aims to address the clinical challenge of CNS involvement in patients with EGFR-mutant cancers—particularly non-small cell lung cancer (NSCLC)—that have progressed following prior treatment. NX-019 is currently being evaluated in first-in-human phase 1 clinical trials for advanced or metastatic EGFR-mutant cancers[1][2][5].